ABSTRACT
Prostate cancer (CaP) remains one of the most frequently diagnosed cancers in men in Western countries for the past decade. The number of new cases projected to be diagnosed in the United States alone in 2007 was estimated at 218, 890, with 27,000 deaths expected from the disease [1].
(PSA) blood test, has been acknowledged by the National Cancer Institute (NCI) as one factor contributing to lowering the mortality rate over the past few years [2-5]. In the mid to late-1980s only one-third of prostate cancers were diagnosed at curable stages compared with today when
